Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [2388]

Why some cancers may respond poorly to key drugs discovered

Why some cancers may respond poorly to key drugs discovered

Cancer survivors urgently need better nutritional support

Cancer survivors urgently need better nutritional support

ESMO 2020: Immunotherapy is beneficial in gastric and oesophageal cancers

ESMO 2020: Immunotherapy is beneficial in gastric and oesophageal cancers

ESMO 2020: Amivantamab with lazertinib in patients with EGFR-mutated non-small cell lung cancer

ESMO 2020: Amivantamab with lazertinib in patients with EGFR-mutated non-small cell lung cancer

ESMO 2020: No benefit for post-operative radiotherapy in non-small-cell lung cancer

ESMO 2020: No benefit for post-operative radiotherapy in non-small-cell lung cancer

ESMO 2020: Sacituzumab govitecan-hziy extends survival in phase 3 ASCENT study of metastatic triple-negative breast cancer

ESMO 2020: Sacituzumab govitecan-hziy extends survival in phase 3 ASCENT study of metastatic triple-negative...

ESMO 2020: New first-line treatment option for metastatic kidney cancer, according to results of phase 3 study

ESMO 2020: New first-line treatment option for metastatic kidney cancer, according to results of phase 3 study

Increasing the effectiveness of immunotherapy against skin cancer

Increasing the effectiveness of immunotherapy against skin cancer

Spotting breast cancer's spread to the brain before symptoms start could improve survival

Spotting breast cancer's spread to the brain before symptoms start could improve survival

ATM inhibition overcomes resistance to histone deacetylase inhibitor

ATM inhibition overcomes resistance to histone deacetylase inhibitor

More from ecancer